| Literature DB >> 12142353 |
Dennis J Selkoe1, Marcia B Podlisny.
Abstract
A remarkable rise in life expectancy during the past century has made Alzheimer's disease (AD) the most common form of progressive cognitive failure in humans. Compositional analyses of the classical brain lesions, the senile (amyloid) plaques and neurofibrillary tangles, preceded and has guided the search for genetic alterations. Four genes have been unequivocally implicated in inherited forms of AD, and mutations or polymorphisms in these genes cause excessive cerebral accumulation of the amyloid beta-protein and subsequent neuronal and glial pathology in brain regions important for memory and cognition. This understanding of the genotype-to-phenotype conversions of familial AD has led to the development of pharmacological strategies to lower amyloid beta-protein levels as a way of treating or preventing all forms of the disease.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12142353 DOI: 10.1146/annurev.genom.3.022502.103022
Source DB: PubMed Journal: Annu Rev Genomics Hum Genet ISSN: 1527-8204 Impact factor: 8.929